back
Ncell

Kantipur Pharmaceuticals IPO Approval Clears Path for 80 Lakh Shares

KATHMANDU : Kantipur Pharmaceuticals IPO approval received official clearance from the Securities Board of Nepal (SEBON) as the company prepares to issue ordinary shares worth Rs 80 crore. Following this regulatory endorsement, Kantipur Pharmaceuticals Lab Limited will release a total of 80 lakh unit shares into the primary capital market. Investors can track official issue pipeline reports directly on the Securities Board of Nepal platform.

Consequently, this approval advances public equity participation within Nepal’s domestic pharmaceutical manufacturing sector. Therefore, institutional and retail market participants are closely monitoring upcoming subscription dates.

Allocation Breakdown for Retail and Other Investors

According to Kantipur Pharmaceuticals IPO approval terms, the company will issue its ordinary shares at a face value of Rs 100 per share:

  • General Public Allocation: Offering 17 lakh shares (21.25 percent of total issuance) specifically for public retail investors.

  • Other Groups Allocation: Reserving 63 lakh shares (78.75 percent of total issuance) for promoters, employees, and designated investor categories.

  • Total Issue Volume: Summarizes to 80 lakh unit shares valued at Rs 800 million.

Furthermore, Muktinath Capital Limited will manage the entire sales and issue management process. To track secondary listings and trading rules, visit the official Nepal Stock Exchange portal. You can also explore our coverage on Vision Lumbini IPO issuance details.

Strategic Significance for Domestic Pharmaceutical Industry

Establishing a public capital base allows pharmaceutical labs to expand domestic production of essential human and veterinary medicines.

Additionally, expanding local manufacturing decreases national reliance on imported pharmaceutical products. Readers can examine industrial trade policies on the Ministry of Industry, Commerce and Supplies portal. For broader financial market updates, read our analysis on Nepal life insurance premium collection Q1 growth.

Primary Market Momentum in Manufacturing

Ultimately, securing SEBON authorization marks a major corporate milestone for pharmaceutical expansion in Nepal.

Thus, Kantipur Pharmaceuticals IPO approval provides fresh momentum for industrial growth within the national stock market.

Published on 2026-11-05 14:31

You can share this post!

400 People Benefit From Free Eye Camp in Kanchanpur; 44 Cataract Cases Identified

400 People Benefit From Free Eye Camp in Kanchanpur; 44 Cataract Cases Identified

Kanchanpur :Around 400 residents received vision care services at a...

Asia Cup Rising Stars: UAE Sets Modest 122-Run Target Against Nepal in Doha

Asia Cup Rising Stars: UAE Sets Modest 122-Run Target Against Nepal in Doha

Kathmandu :The Asia Cup Rising Stars Nepal vs UAE one-day...

Nepal Premier League Season 3: Rijan Dhakal Named Best Player as Sudurpaschim Royals Lift Title

Nepal Premier League Season 3: Rijan Dhakal Named Best Player as Sudurpaschim Royals Lift Title

Kathmandu :The third edition of the Nepal Premier League Season...

Kabaddi Players Practise During Morning Training Session in Lahore

Kabaddi Players Practise During Morning Training Session in Lahore

Kabaddi players practise during a morning training session in Lahore,...